Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience
| Autor: | Stephen Yee, Maria Aguilar, Benny Liu, David Irwin, Priya Patel, Robert J. Wong, Taft Bhuket, Kevin Junus |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Cancer Research HBsAg medicine.medical_specialty Hepatitis B virus Exacerbation medicine.medical_treatment Population medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Hepatitis B Chronic Internal medicine Neoplasms Ethnicity Medicine Humans Mass Screening education Aged CD20 education.field_of_study B-Lymphocytes Hepatitis B Surface Antigens biology business.industry virus diseases Cancer Antibodies Monoclonal Immunosuppression Middle Aged medicine.disease Antigens CD20 Hepatitis B Core Antigens digestive system diseases Oncology 030220 oncology & carcinogenesis Immunology biology.protein 030211 gastroenterology & hepatology Rituximab Female business medicine.drug |
| Zdroj: | Cancer. 123(4) |
| ISSN: | 1097-0142 |
| Popis: | BACKGROUND Individuals with chronic hepatitis B virus infection (HBV) or previously resolved HBV are at increased risk of HBV exacerbation or reactivation when they receive treatment with anti-CD20 monoclonal antibodies (against B-lymphocyte antigen cluster of differentiation 20 [CD20], an activated-glycosylated phosphoprotein) like rituximab (RTX). The objective of the current study was to evaluate the rates of appropriate HBV screening before patients started receiving RTX, at the initiation of HBV treatment, and during HBV flares among an underserved safety-net population. METHODS In total, 244 consecutive adults who received treatment with RTX from 2006 to 2015 at an urban safety-net hospital were evaluated to determine appropriate HBV screening (HBV surface antigen [HBsAg] and HBV total core antibody [HBcAb]) before starting RTX. The initiation of prophylactic antiviral therapy and the development of HBV flares after starting RTX were evaluated. Predictors of appropriate HBV screening were evaluated using multivariate logistic regression models. RESULTS Most patients were women (52.7%; n = 128) and of Hispanic ethnicity (30.7%; n = 74). Before starting RTX, 60.5% (n = 147) of patients received appropriate HBV screening. The HBV screening rates before RTX improved from 14.7% (2006-2009) to 74.7% (2010-2012), and to 87.1% (2013-2015; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text